|
× |
 |
Extensive White Matter Abnormalities and Clinical Symptoms in Drug-Naive Patients With First-Episode Schizophrenia: A Voxel-Based Diffusion Tensor Imaging Study PDF |
$40.00 |
|
$40.00 |
|
× |
|
A Case of Ropinirole-Induced Psychosis PDF |
$40.00 |
|
$40.00 |
|
× |
|
Electroconvulsive Therapy Device Classification: Response to FDA Advisory Panel Hearing and Recommendations PDF |
$40.00 |
|
$40.00 |
|
× |
|
COVID-19 and Infection Control: A Perspective From the Psychiatric Ward PDF |
$40.00 |
|
$40.00 |
|
× |
|
Olanzapine in Refractory Schizophrenia After Failure of Typical or Atypical Antipsychotic Treatment: An Open-Label Switch Study PDF |
$40.00 |
|
$40.00 |
|
× |
|
Cognitive-Behavioral Management of Patients With Bipolar Disorder Who Relapsed While on Lithium Prophylaxis PDF |
$40.00 |
|
$40.00 |
|
× |
|
Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital PDF |
$40.00 |
|
$40.00 |
|
× |
|
Pharmacokinetics, Tolerability, and Clinical Effectiveness of Quetiapine Fumarate: An Open-Label Trial in Adolescents With Psychotic Disorders PDF |
$40.00 |
|
$40.00 |
|
× |
|
The Development of Study Exit Criteria for Evaluating Antimanic Compounds PDF |
$40.00 |
|
$40.00 |
|
× |
|
Life-Threatening Antipsychotic-Induced Ileus PDF |
$40.00 |
|
$40.00 |
|
× |
|
Trajectories of Acute Antidepressant Efficacy: How Long to Wait for Response? A Systematic Review and Meta-Analysis of Long-Term, Placebo-Controlled Acute Treatment Trials PDF |
$40.00 |
|
$40.00 |
|
× |
|
A Brief Review of Dermatitis Artefacta and Management Strategies for Physicians PDF |
$40.00 |
|
$40.00 |
|
× |
|
Brexpiprazole for the Treatment of Tics in a Patient With Schizophrenia PDF |
$40.00 |
|
$40.00 |
|
× |
|
The Current Understanding of Lamotrigine as a Mood Stabilizer PDF |
$40.00 |
|
$40.00 |
|
× |
|
Methylphenidate Transdermal System: A Multisite, Open-Label Study of Dermal Reactions in Pediatric Patients Diagnosed With ADHD PDF |
$40.00 |
|
$40.00 |
|
× |
|
Treatment Journey From Diagnosis to the Successful Implementation of a Long-Acting Injectable Antipsychotic Agent in Young Adults With Schizophrenia PDF |
$0.00 |
|
$0.00 |
|
× |
|
Levomilnacipran for Negative Symptom Domain Schizophrenia PDF |
$40.00 |
|
$40.00 |
|
|
